Upon exposure to exogenous IFN-I/III treatment, these cells adopt a profound antiviral state, highlighting a potential clinical role for recombinant IFNβ or IFNλ1 in chemoprophylaxis and/or therapy of COVID-19. This evidence concerns the gene IFNB1 and COVID-19.